

Erratum

Erratum to: Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma

Yoshihiko Tomita^{1,*}, Go Kimura², Satoshi Fukasawa³,
Kazuyuki Numakura⁴, Yutaka Sugiyama⁵, Kazutoshi Yamana¹,
Sei Naito⁶, Hirokazu Kaneko⁷, Yohei Tajima⁸ and Mototsugu Oya⁹

¹Department of Urology, Molecular Oncology, Graduate School of Medicine and Dental Sciences, Niigata University, Niigata, Japan, ²Department of Urology, Nippon Medical School Hospital, Tokyo, Japan, ³Prostate Center and Division of Urology, Chiba Cancer Center, Chiba, Japan, ⁴Department of Urology, Akita University Graduate School of Medicine, Akita, Japan, ⁵Department of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan, ⁶Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan, ⁷Bristol-Myers Squibb, Tokyo, Japan, ⁸Ono Pharmaceutical Co., Ltd., Osaka, Japan and ⁹Department of Urology, Keio University School of Medicine, Tokyo, Japan

*For reprints and all correspondence: Yoshihiko Tomita, Department of Urology, Niigata University, Asahimachi 1-757, Niigata 951-8510, Japan. E-mail: ytomita@med.niigata-u.ac.jp

Presented at the 58th Annual Meeting of the Japan Society of Clinical Oncology, October 22–25, 2020, at Kyoto, Japan.

Received 24 May 2021; Editorial Decision 28 June 2021; Accepted 5 July 2021

Japanese Journal of Clinical Oncology, doi: <https://doi.org/10.1093/jjco/hyab114>

In the originally published article there were errors in the legends to figures 3 and 4.

Figure 3 should read: “Figure 3. PFS2 of nivolumab (NIVO) or nivolumab and ipilimumab combination therapy (NIVO+IPI). (a) PFS2 of NIVO, stratified by TT regimens after NIVO, sunitinib, or axitinib. (b) PFS2 of NIVO+IPI, stratified by TT regimens after NIVO+IPI, sunitinib, or axitinib, IMDC all risks.” instead of: “Figure 3.OS from first-line therapy of patients treated with nivolumab (NIVO) or nivolumab and ipilimumab combination therapy (NIVO+IPI). (a) OS from first-linetherapy of patients treated with NIVO, stratified by TT regimens after NIVO, sunitinib or axitinib. (b) OS from first-line therapy of patients treated with NIVO+IPI, stratified by TT regimens after NIVO+IPI, sunitinib or axitinib, IMDC all risks.”.

Figure 4 should read: “Figure 4. OS from first-line therapy of patients treated with nivolumab (NIVO) or nivolumab and ipilimumab combination therapy (NIVO+IPI). (a) OS from first-linetherapy of patients treated with NIVO, stratified by TT regimens after NIVO, sunitinib or axitinib. (b) OS from first-line therapy of patients treated with NIVO+IPI, stratified by TT regimens after NIVO+IPI, sunitinib or axitinib, IMDC all risks.” instead of: “Figure 4. PFS2 of nivolumab (NIVO) or nivolumab and ipilimumab combination therapy (NIVO+IPI). (a) PFS2 of NIVO, stratified by TT regimens after NIVO, sunitinib, or axitinib. (b) PFS2 of NIVO+IPI, stratified by TT regimens after NIVO+IPI, sunitinib, or axitinib, IMDC all risks.”.

These errors have now been corrected online.